Rispo Antonio, Capone Pietro, Castiglione Fabiana, Pasquale Luigi, Rea Matilde, Caporaso Nicola
Antonio Rispo, Pietro Capone, Fabiana Castiglione, Matilde Rea, Nicola Caporaso, Division of Gastroenterology, Department of Clinical Medicine and Surgery - University "Federico II" of Naples, 80131 Napoli, Italy.
World J Gastroenterol. 2014 Jul 21;20(27):8947-56. doi: 10.3748/wjg.v20.i27.8947.
Helicobacter pylori (H. pylori) is a widespread pathogen infecting about 40% of people living in urban areas and over 90% of people living in the developing regions of the world. H. pylori is well-documented as the main factor in the pathogenesis of peptic ulcer disease, chronic gastritis, and gastric malignancies such as cancer and mucosa-associated lymphoid tissue-lymphoma; hence, its eradication is strongly recommended. The Maastricht IV consensus, which focused on the management of H. pylori infection, set important new strategies in terms of treatment approaches, particularly with regards to first- and second-line treatment protocols and led to improved knowledge and understanding of H. pylori resistance to antibiotics. In recent years, various fluoroquinolone-based protocols, mainly including levofloxacin, have been proposed and effectively tested at all therapeutic lines for H. pylori eradication. The aim of the present paper is to review the scientific literature focused on the use of fluoroquinolones in eradicating H. pylori.
幽门螺杆菌(H. pylori)是一种广泛传播的病原体,感染了约40%的城市居民以及超过90%的世界发展中地区居民。幽门螺杆菌是消化性溃疡病、慢性胃炎以及胃癌和黏膜相关淋巴组织淋巴瘤等胃部恶性肿瘤发病机制中的主要因素,这一点已有充分记录;因此,强烈建议根除幽门螺杆菌。聚焦于幽门螺杆菌感染管理的马斯特里赫特IV共识在治疗方法方面制定了重要的新策略,特别是在一线和二线治疗方案方面,并增进了对幽门螺杆菌抗生素耐药性的认识和理解。近年来,已经提出了各种以氟喹诺酮类为基础的方案,主要包括左氧氟沙星,并在所有治疗线进行了有效测试以根除幽门螺杆菌。本文的目的是综述聚焦于使用氟喹诺酮类药物根除幽门螺杆菌的科学文献。